Goods & Services

Pharmaceutical preparations, namely wound sprays and wound rinsing solutions for topical application on the skin.

Goods & Services

Chemical, biochemical and biological products, agents, preparations, compounds, reagents and substances for commercial, industrial, scientific and laboratory use; chemical, biochemical and biological products, agents, preparations, compounds, reagents and substances for research, development and production in the fields of human and veterinary medicine, pharmacy, chemistry, biology and biotechnology; industrial detergence for commercial use; detergence for manufacturing processes and for industrial use; chemical, biochemical and biological products, agents, preparations, compounds, reagents and substances as additives and ingredients for medicine, pharmaceutical preparations, medical dressings and plasters, cosmetics, personal and beauty care products and sanitary products; chemical, biochemical and biological products, agents, preparations, compounds, reagents and substances for use in the manufacture of medicine, pharmaceutical preparations, medical dressings and plasters, cosmetics, personal and beauty care products and sanitary products; chemical, biochemical and biological additives and ingredients for use in the manufacture of medicine, pharmaceutical preparations, medical dressings and plasters, cosmetics, personal and beauty care products and sanitary products; chemical, biochemical and biological products, agents, preparations, compounds, reagents and substances for use in medicine, pharmaceutical preparations, medical dressings and plasters, cosmetics, personal and beauty care products and sanitary products; chemical, biochemical and biological raw materials for the formulation of medicine, pharmaceutical preparations, medical dressings and plasters, cosmetics, personal and beauty care products and sanitary products; chemical, biochemical and biological products, agents, preparations, compounds, reagents and substances having antimicrobial and/or virucidal properties, not for medical or veterinary purposes; microorganisms, bacteria and parts thereof, cells and parts thereof, polypeptides, nucleic acids, proteins, lipids, enzymes and enzyme preparations for commercial, industrial, scientific and laboratory use; chemical, biological, biochemical and biotechnological substances for use as additives in personal and beauty care products and in cosmetics. Medicine; pharmaceutical and veterinary preparations; aqueous solution, inhalation solution, solutions for injection, creams, lotions and ointments for pharmaceutical and veterinary purposes; preparations against infectious agents; sanitary preparations for medical and veterinary purposes; virucidal mouth and throat washes; mouth and throat sprays, inhalation solution, solutions for injection, nasal sprays, nasal oils, nasal ointments, nasal creams and nasal drops for medical and veterinary purposes; lozenges for medical purposes; skin disinfectant; medical skin care products; wipes for medical, veterinary and surgical purposes; disinfectants; wipes and medical dressings impregnated with disinfectants or pharmaceutical solutions; chemical, biochemical and biological products, agents, preparations, reagents and substances for medical and veterinary purposes; virucides for medical or veterinary purposes; polypeptides, nucleic acids, proteins, lipids, enzymes and enzyme preparations for medical, veterinary and disinfection purposes; eye washes and eye drops and additives for eye washes and eye drops; feed additives for medical purposes; germicides; cleansing preparations with disinfecting effect for hygienic purposes; medicated animal and livestock washes. Scientific and technology services; research and development services and research work in the fields of medicine, pharmacy, bacteriology, virology, health products, cosmetics and food supplements; research and development consultancy, in particular in the fields of medicine, pharmacy, bacteriology, virology, health products, cosmetics and food supplements; industrial analytical and research services, in particular in the fields of antimicrobial and virucidal analysis and research.

Abstract

The present invention refers to a soluble receptor fragment (SRF) of the ACE-2 receptor, wherein the SRF comprises the peptidase domain (PD) of ACE-2 or a fragment and/or derivates thereof. Moreover, the present invention refers to SRF according to the present invention for use in a method for treatment of the human or animal body by surgery or therapy, as a vaccine or in diagnostic methods practiced on the human or animal body or with fluids or other material from the human or animal body. In addition, the present invention provides SRFs for use in a method of treating and/or preventing a virus infection, in particular a virus infection caused by Coronaviridae, more particularly caused by SARS coronavirus, SARS coronavirus-2, human coronavirus NL63 or SARS-CoV-2. Finally, the present invention relates to a method for capturing viral particles, the method comprises the steps of providing immobilized SRFs and contacting a liquid sample or fluid with the SRFs under conditions for allowing the SRFs to bind the viral particles.

IPC Classes  ?

• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The present invention relates to a polypeptide comprising a Gram negative endolysin and a peptide selected from the group consisting of an antimicrobial peptide, an amphipathic peptide, a cationic peptide, a sushi peptide or a defensin, wherein the endolysin in turn is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and sequences having at least 80% sequence identity with SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and/or SEQ ID NO:9. The present invention relates also to corresponding nucleic acids, vectors, bacteriophages, host cells, compositions and kits. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits in methods for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body. The polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits according to the invention may also be used as an antimicrobial in, e.g., food or feed, in cosmetics, or as disinfecting agent.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A01N 63/50 - Isolated enzymesIsolated proteins
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/04 - Antibacterial agents
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme

Goods & Services

Chemicals, Biochemicals, Biologicals, Chemical materials, Biochemical materials, biological materials, Chemical compositions, Biochemical compounds, biological compounds, Chemical additives, biochemical additives, biological additives, Chemical preparations, biochemical preparations, Biological preparations, Chemical reagents, Biochemical reagents, Biological reagents, Chemical substances for, Biochemical substances, Biological substances for use in industry, Science, For industrial purposes, for laboratory use, Other than for medical or veterinary use; Chemicals, Biochemicals, Biological preparations, Biological preparations, Biological substances, Biologicals, For use in industry, Science, In the field of research, development and production, In relation to the following fields: Human medicine, veterinary medicine, pharmacy, healthcare preparations, Foodstuffs, nutritious supplementary, Dietetic food, Novel food, Functional foods; Chemicals, Biochemicals, Biological preparations, Biological preparations, Biological substances, Biologicals, For use in industry, Science, In the field of research, development and production in the field of human and animal microbiomes, in particular the human and animal gastrointestinal microbiome; Chemicals, Biochemicals, Biological preparations, Biological preparations, Biological substances, Biologicals, For use in industry, Science, In relation to the following fields: Human medicines, veterinary medicines, Pharmaceutical preparations, Healthcare preparations, Foodstuffs, nutritious supplementary, Dietetic food, Novel food, Functional foods; Chemicals, Biochemicals, Biological preparations, Biological preparations, Biological substances, Biologicals, For use in industry, Science, In the field of manufacturing, In relation to the following goods: Human medicines, veterinary medicines, Pharmaceutical preparations, Healthcare preparations, Foodstuffs, nutritious supplementary, Dietetic food, Novel food, Functional foods; Proteins being ingredients, In relation to the following goods: Human medicines, veterinary medicines, Pharmaceutical preparations, Healthcare preparations, Foodstuffs, nutritious supplementary, Dietetic food, Novel food, Functional foods; Proteins for use in manufacture, In relation to the following goods: Human medicines, veterinary medicines, Pharmaceutical preparations, Healthcare preparations, Foodstuffs, nutritious supplementary, Dietetic food, Novel food, Functional foods; All the aforesaid goods included in class 1. Pharmaceutical and veterinary preparations; Drugs for human purposes, Medicines for animals, Natural remedies; proteins for medical purposes; Chemical, biological and biochemical products, Chemical, biochemical and biological materials, compounds, additives, preparations, reagents and substances, For medical use, for veterinary purposes; Vitamin preparations; Dietetic preparations and dietary supplements for humans and animals; Food supplements; Fitness and endurance supplements; Dietary and nutritional preparations; Nutraceutical preparations for human and veterinary use; nutraceutical preparations, For therapeutic purposes, Human medical purposes, for veterinary purposes; Nutritional supplements; Food supplements, not for medical purposes; Goods and preparations for supporting digestion; Goods and preparations for supporting an intact intestinal flora; Goods and preparations for developing an intact intestinal flora; Goods and preparations for supporting an intact microbiome, in particular an intact gastrointestinal microbiome; Goods and preparations for developing an intact microbiome, in particular an intact gastrointestinal microbiome; Goods and preparations for influencing the human and animal microbiome, in particular the human and animal gastrointestinal microbiome; Weight loss products; Appetite suppressants; Functional foods for nutrition or For medical use; Novel food for nutrition or For medical use; Vitamins, Trace elements, proteins, Enzymes, Co-enzymes and amino acids for medical purposes; Lysine preparations; Prebiotic and/or probiotic preparations, not for medical purposes, for dietary supplements; Prebiotic supplements; Probiotic supplements; Medicated supplements for foodstuffs for animals; All the aforesaid goods included in class 5. Science and technology services; Software development and research and Research, in relation to the following fields: Medicine, Pharmacy, Health products, Groceries, nutritional aids, Dietetic foodstuffs, Novel food, Functional foods; Design services; Research and development in the field of the human and animal microbiome; Research and development relating to the influence of the human and animal microbiome; Research and development relating to the effect of the human and animal microbiome on health and wellbeing; Provision of research services, Development services, and, Research, In the field of digestion, intestinal flora and the gastrointestinal microbiome; consultancy relating to research, consulting services related to developing, in relation to the following fields: Medicine, Pharmacy, Healthcare preparations, Groceries, nutritional aids, Dietetic foodstuffs, Novel food, Functional foods; Research and development consultancy relating to the human and animal microbiome, digestion, intestinal flora and the gastrointestinal microbiome; Research, Development, in relation to the following fields: Medicine, Pharmacy, Healthcare preparations, Groceries, nutritional aids, Dietetic foodstuffs, Novel food, Functional foods; Research and development relating to digestion, intestinal flora and the gastrointestinal microbiome; Scientific and industrial analysis and research services, Especially Relating to the human and animal microbiome, digestion, intestinal flora and the gastrointestinal microbiome.

Goods & Services

biochemical and biological preparations and reagents for scientific use, other than for medical or veterinary purposes; biological preparations for industrial use, other than for medical or veterinary purposes; reagents for industrial research purposes, other than for medical or veterinary purposes; biochemical and biological preparations and reagents for research and development in the fields of human and veterinary medicine, pharmacy, biology and biotechnology; industrial detergents for use in manufacturing processes; detergents for use in industrial manufacturing processes; active biochemical and biological ingredients for use in the manufacture of pharmaceutical preparations for treating viruses; active biochemical and biological additives for use in the manufacture of medical dressings; biochemical and biological additives for use in the manufacture of medicine, pharmaceutical preparations, medical dressings and plasters, personal care products and sanitary products; biochemical and biological additives and active biochemical and biological ingredients for use in the manufacture of medicines and pharmaceuticals for treating viral infections, medical dressings and plasters, personal care products and sanitary products; biochemical and biological preparations, for use in the manufacture of pharmaceuticals for treating viral infections; biochemical and biological raw materials for use as active ingredients in the manufacture of pharmaceutical preparations for treating viral infections; biochemical and biological preparations having antimicrobial and/or virucidal properties for scientific research purposes and other than for medical or veterinary purposes; biological, biochemical and biotechnological substances for use as additives in the manufacture of personal care products Medicines for the treatment of viral infections; pharmaceutical preparations for the treatment of viral infections; pharmaceutical preparations in the form of aqueous solution, inhalation solution, and injectable solutions for use in the treatment of viral infections; pharmaceuticals in the form of medicated creams, lotions, and ointments for dermatological use; preparations against infectious agents, namely, disinfectants; sanitary preparations for medical and veterinary purposes; medicated virucidal mouth and throat washes; medicated products for the treatment of viral infections, namely, mouth and throat sprays, nasal sprays, nasal oils, nasal ointments, nasal creams and nasal drops for medical and veterinary purposes; medicated lozenges for medical purposes; skin disinfectant; medicated skin care preparations; antiseptic wipes for medical, veterinary and surgical purposes; disinfectants; wipes and medical dressings impregnated with disinfectants or virucidal pharmaceutical solutions; disinfecting biochemical and biological preparations for medical and veterinary purposes; virucides for medical or veterinary purposes; polypeptides, nucleic acids, proteins, lipids, enzymes and enzyme preparations for medical, veterinary and disinfection purposes; medicated eye washes, medicated eye drops and additives for medicated eye washes and medicated eye drops; animal feed additives for treating infectious diseases; germicides; cleansing preparations with disinfecting effect for hygienic purposes; medicated animal and livestock washes Scientific research in the field of pharmaceuticals; research and development services and research work in the fields of medicine, pharmacy, bacteriology, virology, health products, cosmetics and food supplements; research and development consultancy, in particular in the fields of medicine, pharmacy, bacteriology, virology, health products, cosmetics and food supplements; industrial analytical and research services, in particular in the fields of antimicrobial and virucidal analysis and research

Goods & Services

Chemicals, Biochemicals, Biologicals, Chemical materials, Biochemical materials, biological materials, Chemical compositions, Biochemical compounds, biological compounds, Chemical additives, biochemical additives, biological additives, Chemical preparations, biochemical preparations, Biological preparations, Chemical reagents, Biochemical reagents, Biological reagents, Chemical substances for, Biochemical substances, Biological substances, Relating to the following purposes, commerce, Provision of teaching classes, Industry, laboratories, Other than for medical or veterinary use; Chemicals, Biochemicals, Biological preparations, Biological preparations, Biological substances, Biologicals, All for use in industry, Science, Relating to the following purposes, Research, Development, Products, In relation to the following fields, Human medicine, veterinary medicine, pharmacy, Cosmetology; Chemicals, Biochemicals, Biological preparations, Biological preparations, Biological substances, Biologicals, All for use in industry, Science, In relation to the following fields, Medicinal, Pharmaceutical preparations, Cosmetics, Cosmetic goods; Chemicals, Biochemicals, Biological preparations, Biological preparations, Biological substances, Biologicals, All for use in industry, Science, In relation to the following fields, Production of medicines, pharmaceutical preparations, cosmetics and cosmetic goods; Proteins being ingredients, In relation to the following goods, Medicinal, Pharmaceutical preparations, Cosmetics, Cosmetic goods; Proteins for use in manufacture, In relation to the following goods, Medicinal, Pharmaceutical preparations, Cosmetics, Cosmetic goods; All the aforesaid goods included in class 1; Additives, Ingredients, Ingredients, In relation to the following goods, Cosmetics, namely, Preservatives, Antioxidants, Anti-inflammatory agents, Antimicrobial agent, Amino acids, Lysine, Phages, Proteins, Endolysins, Polypeptides, Enzymes; Additives, Ingredients, Ingredients, In relation to the following goods, Toiletries, namely, Preservatives, Antioxidants, Anti-inflammatory agents, Antimicrobial agent, Amino acids, Lysine, Phages, Proteins, Endolysins, Polypeptides, Enzymes; Additives, Ingredients, Ingredients, In relation to the following goods, Cosmetic preparations, namely, Preservatives, Antioxidants, Anti-inflammatory agents, Antimicrobial agent, Amino acids, Lysine, Phages, Proteins, Endolysins, Polypeptides and Enzymes; Additives, Ingredients, Ingredients, In relation to the following goods, Dermatological skin care preparations, namely, Preservatives, Antioxidants, Anti-inflammatory agents, Antimicrobial agent, Amino acids, Lysine, Phages, Proteins, Endolysins, Polypeptides and Enzymes; Additives, Ingredients, Ingredients, In relation to the following goods, Perfumery preparations, namely, Preservatives, Antioxidants, Anti-inflammatory agents, Antimicrobial agent, Amino acids, Lysine, Phages, Proteins, Endolysins, Polypeptides, Enzymes; Additives, Ingredients, Ingredients, In relation to the following goods, Cosmetic goods, namely, Preservatives, Antioxidants, Anti-inflammatory agents, Antimicrobial agent, Amino acids, Lysine, Phages, Proteins, Endolysins, Polypeptides, Enzymes; Additives, Ingredients, Ingredients, In relation to the following goods, products for the care of the hair, shampoos, namely, Preservatives, Antioxidants, Anti-inflammatory agents, Antimicrobial agent, Amino acids, Lysine, Phages, Proteins, Endolysins, Polypeptides, Enzymes. Cosmetics; Toiletries; Cosmetic preparations for body and beauty care; Dermatological creams [other than medicated]; Non-medicated preparations for the care of the skin; Perfumery; Cosmetic preparations, in particular creams, Cleansing gels, Facial tonics, cleansing peelings, Fluids, Serum, Cover sticks and Lotions; Face and body masks; Preparations for grooming and cleaning the hair; Pads and wipes impregnated with cosmetics; All the aforesaid goods included in class 3. Medicine; Pharmaceuticals, In particular creams, Lotions and ointments for pharmaceutical purposes; Anti-infectives; Sanitary preparations and articles; Preparations for disinfecting skin; Medicated preparations for the care of the skin and hair; Medicated preparations for body and beauty care; Dermatological preparations for skin care; Medicated and sanitising soaps and detergents; proteins for medical purposes; Plasters, material for dressings; wipes for medical or surgical use; Tissues, prep pads, Surgical dressings, Impregnated with pharmaceutical solutions; Chemical, biochemical and biological products, materials, compounds, additives, preparations, reagents and substances For medical use; All the aforesaid goods included in class 5; Biological preparations, biological reagents, For medical use, for veterinary purposes. Science and technology services; Provision of research services, Research, in relation to the following fields, Medicine, Pharmacy, Cosmetology, Body and beauty care; Design services; Research and development consultancy, in relation to the following fields, Medicine, Pharmacy, Cosmetology, Body and beauty care; Research, Development, in relation to the following fields, Medicine, Pharmacy, Cosmetology, Body and beauty care; Scientific and industrial analysis and research services, Especially, in relation to the following fields, Antimicrobial analysis and research.

Abstract

The present invention relates to a polypeptide comprising a Gram negative endolysin and a peptide selected from the group consisting of an antimicrobial peptide, an amphipathic peptide, a cationic peptide, a sushi peptide or a defensin, wherein the endolysin in turn is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and sequences having at least 80% sequence identity with SEQ ID NO:1, SEQ ID NO:2, SEQ ID NOG, SEQ ID NO:4, SEQ ID NOG, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and/or SEQ ID NO:9. The present invention relates also to corresponding nucleic acids, vectors, bacteriophages, host cells, compositions and kits. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits in methods for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body. The polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits according to the invention may also be used as an antimicrobial in, e.g., food or feed, in cosmetics, or as disinfecting agent.

IPC Classes  ?

• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present invention relates to a polypeptide comprising a Gram negative endolysin and a peptide selected from the group consisting of an antimicrobial peptide, an amphipathic peptide, a cationic peptide, a sushi peptide or a defensin, wherein the endolysin in turn is an endolysin comprising a sequence according to SEQ ID NO:1 or SEQ ID NO:2. The present invention relates also to corresponding nucleic acids, vectors, bacteriophages, host cells, compositions and kits. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits in methods for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body. The polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits according to the invention may also be used as an antimicrobial in, e.g., food or feed, in cosmetics, or as disinfecting agent.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme

Abstract

Staphylococcus aureus bacteria. In particular, the present invention relates to polypeptides comprising the CHAP domain of LysK endolysin, the M23 endopeptidase domain of lysostaphin, the cell wall binding domain (CBD) of ALE-1, and a further peptide selected from the group consisting of an antimicrobial peptide, an amphipathic peptide, a cationic peptide, a hydrophobic peptide, a sushi peptide and a defensin. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells, compositions and devices. Finally, the present invention relates to applications of the inventive polypeptides, in particular in the pharmaceutical field.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• A61P 31/04 - Antibacterial agents
• A61L 2/16 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor using chemical substances
• C12N 9/10 - Transferases (2.)
• C12N 9/52 - Proteinases derived from bacteria
• C12N 9/62 - Proteinases derived from fungi from Aspergillus
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/00 - Medicinal preparations containing peptides
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

The present invention relates to antimicrobial agents against Gram-positive bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-positive bacteria and an additional peptide stretch fused to the enzyme at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-positive bacterial infections, as diagnostic means or as cosmetic substance. The present invention also relates to the treatment or prevention of Gram-positive bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Further, the present invention relates to a pharmaceutical composition comprising said fusion protein.

IPC Classes  ?

• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• C12N 9/52 - Proteinases derived from bacteria
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.

IPC Classes  ?

• A61K 38/44 - Oxidoreductases (1)
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C12N 15/56 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. amylase, galactosidase, lysozyme
• C07K 19/00 - Hybrid peptides
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 9/50 - Proteinases
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to the field of antimicrobial agents active against Salmonella bacteria. In particular, the present invention relates to polypeptides comprising a first and a second amino acid sequence, wherein the first amino acid sequence is an endolysin, and wherein the second amino acid sequence is an antimicrobial peptide, cationic peptide, hydrophobic peptide, amphipathic peptide or sushi peptide, and wherein the polypeptide comprises at least one sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 and derivatives thereof. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells. Finally, the present invention relates to applications of the inventive polypeptides, nucleic acids, vectors, and/or host cells, in particular in the pharmaceutical field and in the field of food and feed.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to the field of antimicrobial agents active against Staphylococcus aureus bacteria. In particular, the present invention relates to polypeptides comprising the CHAP domain of LysK endolysin, the M23 endopeptidase domain of lysostaphin, the cell wall binding domain (CBD) of ALE-1, and a further peptide selected from the group consisting of an antimicrobial peptide, an amphipathic peptide, a cationic peptide, a hydrophobic peptide, a sushi peptide and a defensin. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells, compositions and devices. Finally, the present invention relates to applications of the inventive polypeptides, in particular in the pharmaceutical field.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 31/04 - Antibacterial agents
• C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C12N 9/52 - Proteinases derived from bacteria
• A61L 27/00 - Materials for prostheses or for coating prostheses
• A61F 2/07 - Stent-grafts
• A61F 13/00 - Bandages or dressingsAbsorbent pads
• A61M 25/10 - Balloon catheters
• A61L 15/44 - Medicaments
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 38/06 - Tripeptides
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/10 - Peptides having 12 to 20 amino acids

Abstract

The present invention relates to the field of antimicrobial agents active against Enterococcus bacteria. In particular, the present invention relates to a polypeptide comprising a first and a second amino acid sequence, wherein the first amino acid sequence is a sequence selected from SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO: 5; and derivatives thereof; and wherein the second amino acid sequence is an antimicrobial peptide, amphipathic peptide, cationic peptide, hydrophobic peptide, sushi peptide or defensin. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells. Finally, the present invention relates to applications of the inventive polypeptides, nucleic acids, vectors, and/or host cells, in particular in the pharmaceutical field.

IPC Classes  ?

• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme

Abstract

The present invention relates to the field of antimicrobial agents active against Salmonella bacteria. In particular, the present invention relates to polypeptides comprising a first and a second amino acid sequence, wherein the first amino acid sequence is an endolysin, and wherein the second amino acid sequence is an antimicrobial peptide, cationic peptide, hydrophobic peptide, amphipathic peptide or sushi peptide, and wherein the polypeptide comprises at least one sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4 and derivatives thereof. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells. Finally, the present invention relates to applications of the inventive polypeptides, nucleic acids, vectors, and/or host cells, in particular in the pharmaceutical field and in the field of food and feed.

IPC Classes  ?

• C12N 9/50 - Proteinases
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates

Abstract

The present invention relates to methods of eliminating, reducing or preventing bacterial biofilms by means of a fusion protein comprising an endolysin, an autolysin or a bacteriocin to which a peptide with membrane or LPS disrupting activity is fused. Further, the present invention relates to fusion proteins for use as a medicament, in particular for the treatment or prevention of Gram-negative and/or Gram-positive bacterial infections associated with bacterial biofilm, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative and/or Gram-positive bacterial contamination associated with bacterial biofilm of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to the use of said fusion protein as a diagnostic means in medicinal, food or feed or environmental diagnostic associated with bacterial biofilm.

IPC Classes  ?

• C12N 9/14 - Hydrolases (3.)
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C12N 9/52 - Proteinases derived from bacteria
• C12N 15/62 - DNA sequences coding for fusion proteins
• A01N 37/46 - N-acyl derivatives
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to polypeptides comprising an amino sequence selected from the group consisting of: SEQ ID NO: 1, and fragments and derivatives of these. The invention also relates to the corresponding nucleic acids vectors, host cells and compositions. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, host cells and compositions in a method for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body, in particular for the treatment or prevention of Gram-negative bacterial infections. The polypeptides, nucleic acids, vectors, host cells and compositions according to the invention may also be used as an antimicrobial in food or feed, or in cosmetics, as disinfecting agent or in the environmental field.

IPC Classes  ?

• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C12N 9/80 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides
• A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imidesThio-analogues thereof
• A23L 33/18 - PeptidesProtein hydrolysates
• A61K 38/00 - Medicinal preparations containing peptides
• C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/62 - DNA sequences coding for fusion proteins
• A23K 20/147 - Polymeric derivatives, e.g. peptides or proteins
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans

Abstract

Campylobacter bacteria. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells. Finally, the present invention relates to compositions comprising such polypeptides, nucleic acids, vectors, and/or host cells according to the present invention.

IPC Classes  ?

• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Campylobacter bacteria. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells. Finally, the present invention relates to compositions comprising such polypeptides, nucleic acids, vectors, and/or host cells according to the present invention.

IPC Classes  ?

• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• C12N 9/50 - Proteinases

Abstract

The present invention relates to a polypeptide comprising a peptidoglycan hydrolase for use as a medicament for the treatment of chronic bacterial infections. The present invention further relates to a polypeptide comprising a peptidoglycan hydrolase comprising an endopeptidase, N-acetyl-muramoyl-L-alanine-amidase, N-acetyl-muramidase, N-acetyl-glucosaminidase and/or lytic transglycosylase.

IPC Classes  ?

• A61K 38/46 - Hydrolases (3)
• A61P 31/04 - Antibacterial agents

Abstract

The present invention relates to polypeptides comprising an amino sequence selected from the group consisting of: SEQ ID NO: 1, and fragments and derivatives of these. The invention also relates to the corresponding nucleic acids vectors, host cells and compositions. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, host cells and compositions in a method for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body, in particular for the treatment or prevention of Gram-negative bacterial infections. The polypeptides, nucleic acids, vectors, host cells and compositions according to the invention may also be used as an antimicrobial in food or feed, or in cosmetics, as disinfecting agent or in the environmental field.

IPC Classes  ?

• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C12N 9/80 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

The present invention relates to polypeptides comprising an amino acid sequence exhibiting at least about 90% sequence identity with the sequence of SEQ ID NO: 1. Said polypeptides preferably degrade the peptidoglycan of Gram-negative bacteria, in particular of Pseudomonas and/or Campylobacter bacteria. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells. Finally, the present invention relates to compositions comprising such polypeptides, nucleic acids, vectors, and/or host cells according to the present invention.

IPC Classes  ?

• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Mycobacterium species in a sample and a kit comprising the fusion proteins for conduction the methods for the detection.

IPC Classes  ?

• C07K 1/00 - General processes for the preparation of peptides
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12N 9/96 - Stabilising an enzyme by forming an adduct or a compositionForming enzyme conjugates

Abstract

The present invention relates to polypeptides comprising an amino acid sequence exhibiting at least about 90% sequence identity with the sequence of SEQ ID NO: 1. Said polypeptides preferably degrade the peptidoglycan of Gram-negative bacteria, in particular of Pseudomonas and/or Campylobacter bacteria. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells. Finally, the present invention relates to compositions comprising such polypeptides, nucleic acids, vectors, and/or host cells according to the present invention.

IPC Classes  ?

• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C12N 9/50 - Proteinases

Abstract

The present invention relates to polypeptides comprising an amino acid sequence exhibiting at least about 90% sequence identity with the sequence of SEQ ID NO: 1. Said polypeptides preferably degrade the peptidoglycan of Gram-negative bacteria, in particular of Pseudomonas and/or Campylobacter bacteria. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells. Finally, the present invention relates to compositions comprising such polypeptides, nucleic acids, vectors, and/or host cells according to the present invention.

IPC Classes  ?

• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C12N 9/50 - Proteinases

Abstract

The present invention relates to polypeptides comprising an amino acid sequence exhibiting at least about 90% sequence identity with the sequence of SEQ ID NO: 1. Said polypeptides preferably degrade the peptidoglycan of Gram-negative bacteria, in particular of Pseudomonas and/or Campylobacter bacteria. In addition, the present invention relates to nucleic acids encoding such polypeptides, vectors comprising such nucleic acids, and corresponding host cells. Finally, the present invention relates to compositions comprising such polypeptides, nucleic acids, vectors, and/or host cells according to the present invention.

IPC Classes  ?

• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions comprising the same. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.

IPC Classes  ?

• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C07K 19/00 - Hybrid peptides
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C12N 9/50 - Proteinases
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent. The present invention also relates to the use of said polypeptide or fusion protein for the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to a pharmaceutical composition comprising said polypeptide or fusion protein.

IPC Classes  ?

• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• A61K 38/46 - Hydrolases (3)
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to a composition having the activity of degrading the cell wall of a Mycobacterium species comprising: (a) a first fusion protein comprising (i) a first endolysin or a first domain, both having a first enzymatic activity; (ii) at least one peptide stretch fused to the N- or C-terminus of the endolysin having the first enzymatic activity or the domain having the first enzymatic activity, wherein the peptide stretch is selected from the group consisting of synthetic amphipathic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, synthetic antimicrobial peptide (AMP) or naturally occurring AMP; and (iii) a protein transduction domain (PTD) being at the N- or C-terminus of the first fusion protein, wherein the PTD is having the characteristic to deliver a cargo from the extracellular to the intracellular space of a cell; and (b) a second fusion protein comprising (i) a second endolysin or a second domain, both having a second enzymatic activity; (ii) at least one peptide stretch fused to the N- or C-terminus of the endolysin having a second enzymatic activity or the domain having the second enzymatic activity, wherein the peptide stretch is selected from the group consisting of synthetic amphipathic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, synthetic antimicrobial peptide (AMP) or naturally occurring AMP; and (iii) a protein transduction domain (PTD) being at the N- or C-terminus of the second fusion protein, wherein the PTD is having the characteristic to deliver a cargo from the extracellular to the intracellular space of a cell. Moreover, the present invention relates in particular to said composition for use as a medicament, a disinfectant, a feed additive, or a food additive as well as the use of said composition in the treatment or prevention of diseases caused by an infection with a Mycobacterium species.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C07K 19/00 - Hybrid peptides
• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme

Abstract

The present invention relates to a method for the preparation of a mycobacterial lysate comprising the steps of: a) contacting a sample comprising at least one Mycobacterium species with a composition having the activity of degrading the cell wall of a Mycobacterium species, the composition comprising: (a) a first fusion protein including (i) a first endolysin or a first domain, both having a first enzymatic activity, the enzymatic activity being at least one or more of the following: N-acetyl-b-D-muramidase (lysozyme, lytic transglycosylase), N-acetyl-b-D-glucosaminidase, N-acetylmuramoyl-L-alanine amidase, L-alanoyl-D-glutamate (LD) endopeptidase, c-D-glutamyl-meso-diaminopimelic acid (DL) peptidase, L-alanyl-D-iso-glutaminyl-meso-diaminopimelic acid (D-Ala-m-DAP) (DD) endopeptidase, or m-DAP-m-DAP (LD) endopeptidase; and (ii) at least one peptide stretch fused to the N- or C-terminus of the endolysin having the first enzymatic activity or the domain having the first enzymatic activity, wherein the peptide stretch is selected from the group consisting of synthetic amphipathic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, synthetic antimicrobial peptide (AMP) or naturally occurring AMP; and (b) a second fusion protein including (i) a second endolysin or a second domain, both having a second enzymatic activity, the enzymatic activity being at least one or more of the following: lipolytic activity, cutinase, mycolarabinogalactanesterase, or alpha/beta hydrolase; and (ii) at least one peptide stretch fused to the N- or C-terminus of the endolysin having a second enzymatic activity or the domain having the second enzymatic activity, wherein the peptide stretch is selected from the group consisting of synthetic amphipathic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, synthetic antimicrobial peptide (AMP) or naturally occurring AMP; b) incubating the sample for a distinct period, and c) isolating the mycobacterial lysate resulting from step b) thereby obtaining the mycobacterial lysate. Moreover, the present invention relates to the a mycobacterial lysate obtained by the method of the present invention and further to a vaccine composition comprising the mycobacterial lysate, an antibody or antibody fragment generated with the mycobacterial lysate or the vaccine, and a pharmaceutical composition comprising the antibody or antibody fragment.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria

Abstract

The present invention relates to a composition having the activity of degrading the cell wall of a Mycobacterium species comprising: (a) a first fusion protein including (i) a domain with a first enzymatic activity, the enzymatic activity being at least one or more of the following: N-acetyl-b-D-muramidase (lysozyme, lytic transglycosylase), N-acetyl-b-D-glucosaminidase, N-acetylmuramoyl-L-alanine amidase, L-alanoyl-D-glutamate (LD) endopeptidase, c-D-glutamyl-meso-diaminopimelic acid (DL) peptidase, D-Ala-m-DAP (DD) endopeptidase, or m-DAP-m-DAP (LD) endopeptidase, (ii) at least one peptide stretch fused to the N- or C-terminus of the domain with the first enzymatic activity; and (iii) a protein transduction domain (PTD) being at the N- or C-terminus of the first fusion protein; and (b) a second fusion protein including (i) a domain with a second enzymatic activity, the enzymatic activity being at least one or more of the following: lipolytic activity, cutinase, mycolarabinogalactanesterase, or alpha/beta hydrolase; (ii) at least one peptide stretch fused to the N- or C-terminus of the domain of the second enzymatic activity; and (iii) a protein transduction domain (PTD) being at the N- or C-terminus of the second fusion protein for use as a diagnostic agent. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein. In addition, the present invention relates to methods for the detection of a Mycobacterium species in a sample and a kit comprising the fusion proteins for conduction the methods for the detection.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12Q 1/40 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving amylase

Abstract

The present invention relates to methods of eliminating, reducing or preventing bacterial biofilms by means of a fusion protein comprising an endolysin, an autolysin or a bacteriocin to which a peptide with membrane or LPS disrupting activity is fused. Further, the present invention relates to fusion proteins for use as a medicament, in particular for the treatment or prevention of Gram-negative and/or Gram-positive bacterial infections associated with bacterial biofilm, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative and/or Gram-positive bacterial contamination associated with bacterial biofilm of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to the use of said fusion protein as a diagnostic means in medicinal, food or feed or environmental diagnostic associated with bacterial biofilm.

IPC Classes  ?

• C12N 9/14 - Hydrolases (3.)
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C12N 9/52 - Proteinases derived from bacteria

Abstract

The present invention relates to a fusion protein comprising an endolysin with an amino acid sequence according to SEQ ID NO: 1 and fragments and/or derivatives thereof and an additional cationic or polycationic peptide, an amphipatic peptide, a sushi peptide, a defensin, a hydrophobic peptide or an antimicrobial peptide fused to said endolysin, fragment and/or derivative at the N- and/or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, in particular for the treatment or prevention of staphylococcal infections, as diagnostic means, as cosmetic substance or as sanitizing agent. The present invention also relates to the use of said fusion protein for the treatment or prevention of staphylococcal contamination of foodstuff, of food processing equipment, of food processing plants, of feed for livestock animals, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to a pharmaceutical composition comprising said fusion protein.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The application relates to antimicrobial agents against Gram-negative bacteria, in particular to fusion proteins composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and a peptide stretch fused to the enzyme at the N- or C-terminus, as well as pharmaceutical compositions thereof. Moreover, it relates to nucleic acid molecules encoding such a fusion protein, vectors carrying the nucleic acid molecules and host cells transformed with either the nucleic acid molecules or the vectors. In addition, it relates to such a fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means or as cosmetic substance. The application also relates to the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 19/00 - Hybrid peptides
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor
• C12N 15/56 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. amylase, galactosidase, lysozyme
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 9/50 - Proteinases
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent. The present invention also relates to the use of said polypeptide or fusion protein for the treatment or prevention of Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to a pharmaceutical composition comprising said polypeptide or fusion protein.

IPC Classes  ?

• A61K 38/43 - EnzymesProenzymesDerivatives thereof
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme

Abstract

The present invention relates to a fusion protein composed of an enzyme having the activity of degrading the cell wall of Gram-negative bacteria and/or Gram-positive bacteria and at least two peptide stretches fused to the enzyme at the N- or C-terminus, wherein the peptide stretches are distinct and selected from the group of synthetic amphiphatic peptide, synthetic cationic peptide, synthetic polycationic peptide, synthetic hydrophobic peptide, or naturally occurring antimicrobial peptide, like sushi peptide and defensin. Moreover, the present invention relates to nucleic acid molecules encoding said fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said fusion protein for use as a medicament, diagnostic means, cosmetic substance, a disinfectant or a food additive. The present invention also relates to the treatment or prevention of Gram-postive and/or Gram-negative bacterial contamination of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries.

IPC Classes  ?

• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to a fermentation process for the production of an organic compound of interest, wherein the fermentation process comprises the following steps: incubation of components comprising polysaccharides with a phage receptor protein in an aqueous medium and fermentation of the mixture of the incubation step to the organic compound of interest, wherein the organic compound of interest consists of C, H and O atoms only.

IPC Classes  ?

• C12P 7/06 - Ethanol, i.e. non-beverage
• C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention relates to methods of eliminating, reducing or preventing bacterial biofilms by means of a fusion protein comprising an endolysin, an autolysin or a bacteriocin to which a peptide with membrane or LPS disrupting activity is fused. Further, the present invention relates to fusion proteins for use as a medicament, in particular for the treatment or prevention of Gram-negative and/or Gram-positive bacterial infections associated with bacterial biofilm, as diagnostic means, disinfectant or as cosmetic substance. The present invention also relates to the removal or reduction or prevention of Gram-negative and/or Gram-positive bacterial contamination associated with bacterial biofilm of foodstuff, of food processing equipment, of food processing plants, of surfaces coming into contact with foodstuff, of medical devices, of surfaces in hospitals and surgeries. Furthermore, the present invention relates to the use of said fusion protein as a diagnostic means in medicinal, food or feed or environmental diagnostic associated with bacterial biofilm.

IPC Classes  ?

• C12N 9/36 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on beta-1, 4 bonds between N-acetylmuramic acid and 2-acetylamino 2-deoxy-D-glucose, e.g. lysozyme
• C12N 9/52 - Proteinases derived from bacteria

Goods & Services

Chemical, biochemical and biological products, agents, preparations, reagents and substances for commercial, scientific, forensic and laboratory purposes, except for medical and veterinary purposes; chemical, biochemical and biological products, agents, preparations, reagents and substances for research, development and production in the fields of human and veterinary medicine, pharmacy, chemistry, biology, biotechnology, genetics, food technology and environmental technology; bactericides, except for medical and veterinary purpose; diagnostic and analytical agents, preparations and reagents, except for medical and veterinary purposes; microorganisms, bacteria and parts thereof, cells and parts thereof, polypeptides, nucleic acids, proteins, lipids, enzymes and enzyme preparations for commercial, scientific, forensic and laboratory purposes, except for medical and veterinary purposes; preservatives, in particular antimicrobial preservatives, for medicines, for pharmaceutical preparations, for cosmetics and for disinfectants; chemical, biochemical, biological and biotechnological preservatives for food, fodder and beverages; preservatives, in particular antimicrobial preservatives, for the manufacture of medicines, pharmaceutical preparations, cosmetics, disinfectants, food, in particular meat and meat products, fodder and beverages; chemical, biochemical, biological and biotechnological products for horticulture, agriculture, fish farming and forestry, except fungicides, herbicides, insecticides and agents for control of parasites; chemical, biochemical, biological and biotechnological products for the treatment, purification and disinfection of water; water purification agents; chemical, biological, biochemical and biotechnological substances for use as additives in food, fodder, beverages and cosmetics. Detergents; laundry soaking agents; dishwashing detergents; household detergents; cleaning preparations; cloths impregnated with a detergent for cleaning; soaps, in particular disinfecting, deodorant and medicated soaps; hand cleaning preparations and hand detergents; cosmetics; perfumeries; body and beauty care cosmetics, in particular creams, lotions, sun screen and tanning creams and lotions; hair care and hair cleaning preparations; mouth care preparations, not for medical purposes; dentifrices. Medicines; pharmaceutical and veterinary products, in particular creams, lotions and ointments for pharmaceutical and veterinary purposes; preparations against infectious agents; sanitary preparations for medical use, in particular antibacterial mouth washes, skin disinfectants, medical skin and hair care preparations; plasters and dressing materials; wiping clothes for medical and surgical purposes; disinfectants; cloths and dressing materials impregnated with disinfectants and pharmaceutical solutions; chemical, biochemical and biological products, agents, preparations, reagents and substances for medical and veterinary purposes; bactericides for medical and veterinary purposes; diagnostic and analytical agent, preparations and reagents for medical and veterinary purposes; microorganisms, bacteria and parts thereof, cells and parts thereof, polypeptides, nucleic acids, proteins, lipids, enzymes and enzyme preparations for medical, veterinary and disinfection purposes; eye washes and drops; contact lens cleaning and caring preparations as well as contact lens solutions; fodder additives for medical purposes; germicides; disinfecting cleaning preparations; animal and cattle washes.